MC-207110
Based on 12 publication(s) in Google Scholar
MC-207110 is a broad-spectrum efflux pump inhibitor. MC-207110 is active against all three known Mex efflux pumps from P. aeruginosa and their close Escherichia coli efflux pump homolog (AcrAB-TolC). MC-207110 can decrease the intrinsic resistance of P. aeruginosa to fluoroquinolones. MC-207110 can be used for the research of infection .
For research use only. We do not sell to patients.
- CAS No.: 115871-02-8
- Formula: C25H30N6O2
- Molecular Weight:446.54
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) MC-207110
More- Cell Rep. 2025 Jul 22;44(7):115987. [Abstract]
- Front Microbiol. 2024 Sep 24:15:1417237. [Abstract]
- Front Cell Infect Microbiol. 2021 Mar 25:11:660431. [Abstract]
- World J Microbiol Biotechnol. 2024 Jun 6;40(8):233. [Abstract]
- Microbiol Spectr. 2026 Jul 7;14(7):e0410825. [Abstract]
- Microbiol Spectr. 2025 Sep 2;13(9):e0114425. [Abstract]
- J Antimicrob Chemother. 2021 Dec 24;77(1):58-68. [Abstract]
- mSphere. 2023 Apr 20;8(2):e0067322. [Abstract]
- Microb Pathog. 2023 Dec:185:106397. [Abstract]
- Microb Drug Resist. 2020 Jun;26(6):550-560. [Abstract]
- Al-Rafidain Journal of Medical Sciences. 2025 Feb 11.
- bioRxiv. 2020 Apr.
-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
-
Bio/Physico-chemical Assay
-
Microbiological Assay
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | CC50 |
>100 μM
Compound: PAbetaN
|
Cytotoxicity against HEK293 cells incubated for 24 hrs by MTT assay
Cytotoxicity against HEK293 cells incubated for 24 hrs by MTT assay
|
[PMID: 37672933] |
| LX-2 | CC50 |
>100 μM
Compound: PAbetaN
|
Cytotoxicity against human LX2 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human LX2 cells incubated for 24 hrs by MTT assay
|
[PMID: 37672933] |
Chemical Information
-
CAS No. 115871-02-8
-
Molecular Weight 446.54
-
Formula C25H30N6O2
-
SMILES
O=C([C@H](CCCNC(N)=N)NC([C@H](CC1=CC=CC=C1)N)=O)NC2=CC(C=CC=C3)=C3C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
Lon dysfunction-mediated collateral sensitivity drives effective antibiotic combination therapies against tigecycline-resistant pathogens. [Abstract]2025 Jul 22;44(7):115987. PMID: 40650911
MC-207110 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Jul 22;44(7):115987. [Abstract]
Effect of efflux pump inhibitors (CCCP (10 mg/L), NMP (25 mg/L ), and PAβN dihydrochloride (25 mg/L)) on the susceptibility of evolved strains to tigecycline (n = 2). PAβN dihydrochloride lowered the MIC values and reversed the tigecycline-resistance phenotypes, suggesting a role for increased efflux pump activity in tigecycline resistance.
-
Front Microbiol
Comparison of antimicrobial activities and resistance mechanisms of eravacycline and tigecycline against clinical Acinetobacter baumannii isolates in China. [Abstract]2024 Sep 24:15:1417237. PMID: 39380684
MC-207110 purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2024 Sep 24:15:1417237. [Abstract]
The results of tigecycline combined with PAβN dihydrochloride (20 mg/L) demonstrated that 20 TNSKP strains exhibited a fold decrease ≥ 4 in MIC after co-incubation with PAβN, but 2 strains of TSKP did not show any change in MIC under the effect of efflux pump inhibitor.
-
Front Cell Infect Microbiol
A Potential Combination Therapy of Berberine Hydrochloride With Antibiotics Against Multidrug-Resistant Acinetobacter baumannii. [Abstract]2021 Mar 25:11:660431. PMID: 33842399
MC-207110 purchased from MedChemExpress. Usage Cited in: Front Cell Infect Microbiol. 2021 Mar 25:11:660431. [Abstract]
BBH uptake with pump inhibitors CCCP, PAβN dihydrochloride (50 µM; 60 min), and reserpine in ATCC 19606 strain, MDR-B and △adeB MDR-B strains, and MDR-TJ and △adeB MDR-TJ strains. Red arrows indicate the pump inhibitors (50 µM) were added at 60 min. Grey letters indicate the inhibitors were added to the adeB knockout strains.
-
World J Microbiol Biotechnol
AcrAB-TolC efflux pump overexpression and tet(A) gene mutation increase tigecycline resistance in Klebsiella pneumoniae. [Abstract]2024 Jun 6;40(8):233. PMID: 38842631 -
Microbiol Spectr
OmpK36 deficiency and inducible AmpC β-lactamase synergistically drive imipenem resistance in Klebsiella aerogenes. [Abstract]2026 Jul 7;14(7):e0410825. PMID: 42212662 -
Microbiol Spectr
IITR00803: a benzoxazole-nitrothiophene small molecule with broad-spectrum antibacterial potential. [Abstract]2025 Sep 2;13(9):e0114425. PMID: 40792514 -
J Antimicrob Chemother
Identification of a novel plasmid-mediated tigecycline resistance-related gene, tet(Y), in Acinetobacter baumannii. [Abstract]2021 Dec 24;77(1):58-68. PMID: 34634801 -
mSphere
RND Pump-Mediated Efflux of Amotosalen, a Compound Used in Pathogen Inactivation Technology to Enhance Safety of Blood Transfusion Products, May Compromise Its Gram-Negative Anti-Bacterial Activity. [Abstract]2023 Apr 20;8(2):e0067322. PMID: 36853056 -
Microb Pathog
Effect of piperine on the inhibitory potential of MexAB-OprM efflux pump and imipenem resistance in carbapenem-resistant Pseudomonas aeruginosa. [Abstract]2023 Dec:185:106397. PMID: 37852553
MC-207110 purchased from MedChemExpress. Usage Cited in: Microb Pathog. 2023 Dec:185:106397. [Abstract]
PAβN dihydrochloride (50 μg/mL; 50 μL; 24 h)。 Results of screening test strains.
-
Microb Drug Resist
Site-Directed Mutagenesis Reveals Crucial Residues in Escherichia coli Resistance-Nodulation-Division Efflux Pump OqxB. [Abstract]2020 Jun;26(6):550-560. PMID: 31834851
MC-207110 purchased from MedChemExpress. Usage Cited in: Microb Drug Resist. 2020 Jun;26(6):550-560. [Abstract]
PAβN dihydrochloride (50-200 μg/mL) and NMP inhibited OqxB activity in a concentration-dependent manner, suggesting that an efflux pump (OqxAB) is indeed responsible for the decreased susceptibility of the overexpression system.
-
-
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)